tbuckley/cabot-search huggingface dataset:
Recommended healthcare among elderly cancer survivors
Authors: A. M. McBean, X. Yu, B. A. Virnig
Journal: Journal of Clinical Oncology (2006)

6045 Background: Earle and colleagues (2003, 2004) have published conflicting information regarding recommended services among cancer survivors: breast cancer survivors had higher rates than persons without cancer (2003); and colorectal cancer survivors had lower rates (2004). We examined the use of preventive services and recommended diabetes care in 1999–2002 among elderly Medicare beneficiaries who were long-term survivors of 5 different types of cancer: bladder, breast, colorectal, prostate and uterine. Methods: Retrospective cohort analysis using the linked SEER/Medicare database of beneficiaries living in the SEER areas of the NCI who survived 5 years after bladder, breast, colorectal, prostate or uterine cancer diagnosis and a 5% random sample of beneficiaries with no cancer history residing these areas. We compared the rates of influenza vaccination and breast cancer screening, as well as diabetes care services: hemoglobin A1c (HbA1c) testing, eye examination, and lipid testing. Crude and multivariate adjusted rates were calculated and compared. Results: In 1999 through 2002, depending on the cancer type and year, cancer survivors were between 20 and 50% more likely to receive influenza vaccine or mammograms than persons who never had cancer (women with breast cancer excluded). Among those cancer survivors with diabetes, the rates of annual HbA1c testing or eye examination were 1 to 16% greater in all years than among those without cancer, p &lt; 0.05, when adjusted for age-group, gender (if needed), and race. Differences in the serum lipid level determination rates were even smaller or not significant (p ≥ 0.05) between the cancer survivors and controls. Interestingly, depending on the cancer type, the rates of influenza vaccination and mammography were up to 30% higher among cancer survivors with diabetes than in survivors who did not have diabetes. Multivariate models that included other sociodemographic variables, comorbities and other relevant covariates confirmed these findings. Conclusions: Elderly persons who have survived cancer were generally more likely to receive preventive and other recommended services compared with those without cancer. The presence of another chronic disease such as diabetes, may enhance the use of preventive services. No significant financial relationships to disclose.
Association between genetic variations in transforming growth factor beta pathway and overall survival in patients with non-small cell lung cancer treated with definitive radiotherapy.
Authors: Weili Wang, Kerby A Shedden, Feng-Ming (Spring) Kong
Journal: Journal of Clinical Oncology (2012)

e17530 Background: The transforming growth factor beta (TGFβ) pathway, an important regulator in cellular metabolic process, has been reported for significant association with cancer prognosis. This study was to exam the association between single nucleotide polymorphisms (SNPs) of TGFβ pathway and overall survival (OS) in subjects with non-small cell lung cancer (NSCLC). Methods: Patients with stage I-III NSCLC received definitive radiotherapy with/without chemotherapy were eligible to this prospective study. The primary endpoint was OS which was calculated from radiation treatment start to death or censored. DNA samples for genotyping were extracted from buffy-coat which was collected before commencement of treatment. 19 SNPs in 10 genes (BMP1, BMP2, INHBC, SMAD1, SMAD3, SMAD4, SMAD6, SMAD7, SMAD8, TGFβ1), which was reported to have significant correlation with OS of lung cancer, were selected. MassArray System (Sequenom Company) was used for genotyping. Cox regression was performed for multivariate analysis to examine the effects of genotypes on OS using dominant and recessive genetic model. Results: 126 consecutive patients, 91% of them were Caucasian, were recruited in this study. All SNPs call rates were over 90%. Assay reproducibility was over 99% by random double-blinding duplicate or triplicate genotyping. Among clinical factors analyzed, radiation dose was only significant independent factor predicting OS (P=0.001). Genotypic association study showed that 7 SNPs (rs235756, rs11939979, rs12102171, rs6494633, rs12456284, rs12906898 and rs4803455) were significantly associated with OS, adjusted for age, gender, smoking, histology, clinical stage, tumor volume, Karnofsky Performance Status, radiotherapy dose, and chemotherapy. The strongest association was in SMAD3: rs12102171 (P=0.004, HR=2.28, 95%CI, 1.26-4.15). Conclusions: This study partly validated findings from previous studies that genetic variations in the TGFβ pathway are significant predictors of overall survival in NSCLC patients treated with definitive radiotherapy with/without chemotherapy.
Effect of Mandatory 6‐Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma
Authors: Shunji Nagai, Toshihiro Kitajima, Sirisha Yeddula, Reena Salgia, Randolph Schilke, Marwan S. Abouljoud, Dilip Moonka
Journal: Hepatology (2020)

Background and Aims Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) policy mandates a 6‐month waiting period before exception scores are granted to liver transplant candidates with hepatocellular carcinoma (HCC). This study aims to evaluate waitlist and posttransplant outcomes in patients with HCC, before and after implementation of the 6‐month waiting rule. Approach and Results We examined two groups from the UNOS registry: Group 1 (pre‐6‐month rule) consisted of patients registered as transplant candidates with HCC from January 1, 2013, to October 7, 2015 (n = 4,814); group 2 (post‐6‐month rule) consisted of patients registered from October 8, 2015, to June 30, 2018 (n = 3,287). As expected, the transplant probability was higher in the first 6 months after listing in group 1 than group 2 at 42.0% versus 6.3% ( P &lt; 0.001). However, the 6‐month waitlist mortality/dropout rate was lower in group 2 at 1.2% than group 1 at 4.1% ( P &lt; 0.001). To assess regional parity of transplant, UNOS regions were categorized into three groups based on Model for End‐Stage Liver Disease score at transplant: lower‐score (regions 3, 10, and 11), middle‐score (1, 2, 6, 8, and 9), and higher‐score region groups (4, 5, and 7). Outcomes were compared from the time exception points were given, which we defined as conditional waitlist outcomes. Conditional waitlist mortality/dropout decreased, and transplant probability increased in all region groups, but the benefits of the policy were more pronounced in the higher and middle‐score groups, compared with the lower‐score group. The decline in waitlist mortality/dropout was only significant in the high Model for End‐Stage Liver Disease group ( P &lt; 0.001). No effect was observed on posttransplant mortality or percent of patients within Milan criteria on explant. Conclusions The HCC policy change was associated with decreased waitlist mortality/dropout and increased transplant probability. The policy helped to decrease but did not eliminate regional disparities in transplant opportunity without an effect on posttransplant outcomes.
TRENDS IN SURGICAL LEFT ATRIAL APPENDAGE CLOSURE IN PATIENTS UNDERGOING VALVULAR HEART SURGERY FROM 2010 TO 2014: RESULTS FROM THE NATIONAL INPATIENT SAMPLE (NIS) DATABASE
Authors: Rakhee R Makhija, Sarah Westcott, Thomas W. Smith, Jason Rogers, Gagan Singh
Journal: Journal of the American College of Cardiology (2020)
Cardiac tumors prevalence and mortality: A systematic review and meta-analysis
Authors: Mohamed Rahouma, Mohammed J. Arisha, Adham Elmously, Magdy M. El-Sayed Ahmed, Cristiano Spadaccio, Kritika Mehta, Massimo Baudo, Mohamed Kamel, Esraa Mansor, Yongle Ruan, Mahmoud Morsi, Shon Shmushkevich, Ihab Eldessouki, Mostafa Rahouma, Abdelrahamn Mohamed, Ivancarmine Gambardella, Leonard Girardi, Mario Gaudino
Journal: International Journal of Surgery (2020)
Contralateral parotid volume as an objective marker for adaptive radiotherapy in head and neck cancer.
Authors: Patrick James Gagnon, Anna Simeonova, Martin Fuss, Sheri Weintraub, Charles R. Thomas, John M Holland
Journal: Journal of Clinical Oncology (2012)

5596^ Background: Deformable image registration simplifies the process of adaptive radiotherapy and allows for sophisticated dosimetric analyses of anatomic changes. Lacking is an objective measurement that could reliably predict for undesirable dosimetric changes during a course of radiotherapy. We analyzed daily changes in contralateral parotid volume and correlated these changes to mean dose delivered to the parotid gland over a course of radiotherapy in four patients. Methods: Daily cone-beam CT (CBCT) scans of four patients were imported into the MIM Maestro software. The simulation CT scan was registered to 35 daily CBCT’s per patient using a sequence of rigid and deformable registrations. Parotid contours were resampled and a deformed reconstruction of the planning CT was exported to the Eclipse treatment planning software. The CT reconstructions were extended superiorly and inferiorly and the original fluence map was re-computed on the reconstructions with the isocenter at daily treatment position. Mean dose percent change and mean volume percent change were calculated for all CBCT’s and averaged across all patients. Average mean dose percent change was plotted against average mean volume change and evaluated with simple regression analysis. Results: A mean of 31 CBCT’s per patient were evaluated. Contralateral parotid volume percent changes for all patients were -31%, -40%, -40%, and -22% with a mean percent change of -33%. Mean dose percent changes were 25%, 35%, 19%, and 25% with a mean percent change of 26% and a mean absolute dose increase to the parotids of 6.8 Gy. Simple regression analysis identified a coefficient of determination (R 2 ) of 0.23 where the independent variable is volume percent change and the dependent variable is mean dose percent change. Conclusions: Daily or weekly volume assessment of critical volumes is feasible utilizing deformable image registration and CBCT. Our data suggests there may be a correlation between parotid volume changes and increases in mean parotid dose though no causality is inferred. This relationship could be useful as a simple objective volumetric threshold measurement to prompt adaptive re-planning and warrants further investigation.
IMPACT OF DESIGN FEATURES OF CONTEMPORARY DRUG-ELUTING STENTS ON CLINICAL OUTCOMES: A COMPARATIVE META-ANALYSIS
Authors: Mohamed Abo-Aly, Naoki Misumida, Christian Deutsch, Bennet George, Gbolahan Ogunbayo, Adrian Messerli, Ahmed Abdel-Latif, Khaled Ziada
Journal: Journal of the American College of Cardiology (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Authors: Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Désirée van der Heijde, Iain B McInnes
Journal: The Lancet (2020)
Involvement of compensatory CD44+ stem cells following BCL-2 suppression by antisense oligonucleotides.
Authors: Marvin Rubenstein, Courtney M.P. Hollowell, Patrick Guinan
Journal: Journal of Clinical Oncology (2013)

2590 Background: Gene therapy is in theory specific but encounters difficulties in practice. Suitable targets are found in many pathways and tumors do express altered patterns of expression. However the actual activity of most regulatory genes are similar to normal. Resistance develops because biochemical pathways are complex, regulated by stimulatory and inhibitory factors, each possibly affected by therapy. It’s suggested that tumors alter dependence on targeted gene products for growth by relying upon others, through compensation. Antisense oligos have targeted regulatory proteins in both in vivo and in vitro prostate cancer models. Cells treated with antisense directed against bcl-2 compensated by suppressing caspase-3 (an apoptosis promoter) and enhancing androgen receptor (AR), (co-activating) p300 and IL-6 expression. This suggests that in LNCaP a progression to increased androgen sensitivity accompanies bcl-2 suppression with a pattern of co-activation associated with more advanced prostate tumors. Methods: We evaluated mono- and bispecific oligos which targeted and equally suppressed bcl-2 expression in LNCaP cells. To further evaluate compensatory mechanisms related to tumor resistance we evaluated the level of CD44 expression employing RT-PCR and agarose gel quantification. Bands representing pcr product were photographed, converted to black and white and assessed by MIPAV software. Results: Comparable amounts of RNA from LNCaP cells treated with either mono- or bispecific oligos directed against bcl-2 (and EGFR in the bispecifics) were evaluated by RT-PCR using primers directed against CD44. When background intensity was subtracted, the relative intensity of the bands corresponding to CD44, and representing cells treated with MR 4 , MR 24 and MR 42 (compared to controls) were respectively increased 3.0% ± 33.6 (NS), suppressed 16.4% ± 49.1 (NS) and suppressed 9.2% ± 26.5 (NS). These results were pooled from both duplicate PCR runs and gels, and indicate no significant changes in CD44 expression was produced by any oligo type. Conclusions: Stem cells expressing this marker were unaffected by treatment, suggesting this population is not altered by suppressive bcl-2 therapy.
EFFECTS OF SYMPATHETIC BLOCKADE ON RESPONSIVENESS TO VNS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
Authors: Inderjit Anand, Jeffrey L. Ardell, Douglas Gregory, Imad Libbus, Lorenzo Dicarlo, Rajendra Premchand, Kamal Sharma, Sanjay Mittal, Rufino Monteiro
Journal: Journal of the American College of Cardiology (2020)
LEFT CARDIAC SYMPATHECTOMY DENERVATION IN A PATIENT WITH LONG QT SYNDROME UNRESPONSIVE TO BETA-BLOCKERS AND CARDIAC PACING
Authors: Hector Guillermo Betancourt Del Campo, Gerardo Emilio Pozas Garza, Carlos Sanchez Diaz, José Gildardo Paredes-Vázquez, Hernan Azpiri, Hector Lopez de la Garza, Jaime Alberto Guajardo Lozano, David Rodriguez, Jathniel Panneflek, Vicente Jimenez Franco
Journal: Journal of the American College of Cardiology (2020)
CLO20-036: Comparative Outcomes of Patients With Locoregional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated With Definitive Therapy
Authors: Cole Friedes, Nick Mai, Wei Fu, Peijin Han, Ranh Voong, Russell Hales
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-036: Comparative Outcomes of Patients With Locoregional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated With Definitive Therapy" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer
Authors: Steven H. Lin, Brian P. Hobbs, Vivek Verma, Rebecca S. Tidwell, Grace L. Smith, Xiudong Lei, Erin M. Corsini, Isabel Mok, Xiong Wei, Luyang Yao, Xin Wang, Ritsuko U. Komaki, Joe Y. Chang, Stephen G. Chun, Melenda D. Jeter, Stephen G. Swisher, Jaffer A. Ajani, Mariela Blum-Murphy, Ara A. Vaporciyan, Reza J. Mehran, Albert C. Koong, Saumil J. Gandhi, Wayne L. Hofstetter, Theodore S. Hong, Thomas F. Delaney, Zhongxing Liao, Radhe Mohan
Journal: Journal of Clinical Oncology (2020)

Whether dosimetric advantages of proton beam therapy (PBT) translate to improved clinical outcomes compared with intensity-modulated radiation therapy (IMRT) remains unclear. This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these modalities for esophageal cancer.This phase IIB trial randomly assigned patients to PBT or IMRT (50.4 Gy), stratified for histology, resectability, induction chemotherapy, and stage. The prespecified coprimary end points were TTB and PFS. TTB, a composite score of 11 distinct adverse events (AEs), including common toxicities as well as postoperative complications (POCs) in operated patients, quantified the extent of AE severity experienced over the duration of 1 year following treatment. The trial was conducted using Bayesian group sequential design with three planned interim analyses at 33%, 50%, and 67% of expected accrual (adjusted for follow-up).This trial (commenced April 2012) was approved for closure and analysis upon activation of NRG-GI006 in March 2019, which occurred immediately prior to the planned 67% interim analysis. Altogether, 145 patients were randomly assigned (72 IMRT, 73 PBT), and 107 patients (61 IMRT, 46 PBT) were evaluable. Median follow-up was 44.1 months. Fifty-one patients (30 IMRT, 21 PBT) underwent esophagectomy; 80% of PBT was passive scattering. The posterior mean TTB was 2.3 times higher for IMRT (39.9; 95% highest posterior density interval, 26.2-54.9) than PBT (17.4; 10.5-25.0). The mean POC score was 7.6 times higher for IMRT (19.1; 7.3-32.3) versus PBT (2.5; 0.3-5.2). The posterior probability that mean TTB was lower for PBT compared with IMRT was 0.9989, which exceeded the trial's stopping boundary of 0.9942 at the 67% interim analysis. The 3-year PFS rate (50.8% v 51.2%) and 3-year overall survival rates (44.5% v 44.5%) were similar.For locally advanced esophageal cancer, PBT reduced the risk and severity of AEs compared with IMRT while maintaining similar PFS.
Clinical outcome of 1,968 cases of meningiomas from Kaiser Permanente Northern California.
Authors: Nathalie T. Nguyen, Liisa L Lyon, Gregory S Moes, Kamran Sahrakar, John L. Villano
Journal: Journal of Clinical Oncology (2013)

2062 Background: Meningioma is the most common primary brain tumor in the United States, but there is limited data on clinical outcomes. Methods: We performed descriptive and survival analysis of meningioma cases diagnosed 2001-2010 from the Kaiser Permanente Northern California Cancer Registry, which began inclusion of benign brain tumors in 2001. Datasets provided variables on gender, age at diagnosis, race, and vital status. Chart review extracted additional information on mortality, histology, imaging, tumor size, tumor site, and treatment. We used Kaplan Meier method to calculate overall survival (OS) and disease-free survival (DFS) and log-rank test to compare survival rates by variables. Cox proportional hazard models were used to analyze variables relative to endpoints. Results: 1968 cases in 1792 patients with meningioma were analyzed. 55% of cases had histological confirmation. 5- and 10-year OS and DFS for all groups were 76% &amp; 61% and 89% &amp; 82%. Disease progression and recurrence presented in 10% of cases at 10 years, resulting in 4% disease-specific mortality (DSM). Statistically significant prognostic factors of worse DFS were age &gt;= 80, WHO grade 2-3, tumor size &gt;= 18 mm, peritumoral edema on imaging, Simpson grades (SG) 4 or 5, and no surgery. Factors associated with significantly worse OS included age &gt;= 60, male gender, tumor size &gt;= 42 mm, peritumoral edema, SG 4 or 5, no histology and no treatment (NT). SG 1-3 groups provided statistically the highest OS and DFS. There was no significant difference in DFS or OS for definitive RT versus surgery and adjuvant RT groups. Definitive RT showed significantly better OS than NT (HR=0.46, 95% CI: 0.21-0.98). Cases with progression or recurrence had 51% DSM with 65% of deaths associated with lack of salvage therapy. Salvage RT provided better OS benefit compared to other salvage groups (HR=0.35, 95% CI: 0.14-0.91). Conclusions: We demonstrated favorable long-term outcome for meningiomas and confirmed the prognostic benefit of Simpson grading. We have identified additional adverse factors affecting outcome. While surgery remains standard, definitive RT demonstrates comparable outcome to cases not amenable to gross total resection. Salvage RT is effective, providing a survival benefit.
CHEST PAIN TREATED WITH AN ESOPHAGEAL STENT, ESOPHAGEAL RUPTURE MIMICKING INFEROLATERAL ST ELEVATION MYOCARDIAL INFARCTION WITH JUNCTIONAL RHYTHM
Authors: Wytch Rigger, Raymond Mai, Paul Maddux, Yaser Nemshah, Joe Calkins, Stuart Cavalieri
Journal: Journal of the American College of Cardiology (2020)
HSR20-104: Treatment Patterns and Time Trends for Intrahepatic Cholangiocarcinoma (iCCA) Patients: A Real-World Retrospective Claims Study
Authors: Shreekant Parasuraman, Lincy Lal, Scott Bunner, Dilan Paranagama, Anna Teschemaker, Susan Snodgrass, Smitha Sivaraman
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-104: Treatment Patterns and Time Trends for Intrahepatic Cholangiocarcinoma (iCCA) Patients: A Real-World Retrospective Claims Study" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
Authors: Masayuki Tahara, Tomoko Oeda, Kazumasa Okada, Takao Kiriyama, Kazuhide Ochi, Hirofumi Maruyama, Hikoaki Fukaura, Kyoichi Nomura, Yuko Shimizu, Masahiro Mori, Ichiro Nakashima, Tatsuro Misu, Atsushi Umemura, Kenji Yamamoto, Hideyuki Sawada
Journal: The Lancet Neurology (2020)
A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer.
Authors: Muhammad Yaser Nasim, Ruth Plummer, T.R. Jeffry Evans, Rosemary Morrison, David Alan Anthoney, Sophie Haney, Ayman Madi, Claudio Isaac Savulsky, Claire Johnston, David Carter, Larisa Reyderman, Prashanth Gopalakrishna, Jantien Wanders, Christopher Twelves
Journal: Journal of Clinical Oncology (2012)

2552 Background: Eribulin mesylate is a microtubule dynamics inhibitor approved by FDA for patients (pts) with metastatic breast cancer after treatment with at least two prior chemotherapeutic regimens. This Phase Ib, open-label dose-escalation study determined the maximum tolerated dose (MTD) of eribulin in combination with capecitabine. Methods: Pts with advanced solid malignancies refractory to standard therapies, adequate organ function and ECOG performance status ≤2 received eribulin mesylate (2–5-min IV) by Schedule 1 (1.2, 1.6 or 2.0 mg/m 2 on Day 1) or Schedule 2 (0.7, 1.1 or 1.4 mg/m 2 on Days 1 and 8), in combination with twice-daily oral capecitabine 1000 mg/m 2 Days 1-14 every 21 days. The MTD was defined as the highest dose in each schedule where ≤1/6 pts experienced dose-limiting toxicity (DLT). Safety and pharmacokinetics (PK) were assessed. Results: Of the 34 pts recruited, 19 (53% male; median age 62 years; 42% ECOG 0, 58% ECOG 1) and 15 (33% male; median age 61 years; 33% ECOG 0, 60% ECOG 1, 7% ECOG 2) were enrolled in Schedules 1 and 2, respectively. Most common tumor types were large intestine (20.6%), lung/bronchus (17.7%) and breast (14.7%). DLTs are shown in the table; there were no unexpected toxicities with the combination. The MTD for eribulin mesylate was 1.6 and 1.4 mg/m 2 for Schedules 1 and 2, respectively, in combination with capecitabine 1000 mg/m 2 twice-daily. Eribulin PK were dose proportional and independent of schedule or capecitabine co-administration. Combination with eribulin had no effect on the disposition of capecitabine and its metabolites. Although sample size was small, preliminary signs of efficacy were observed. Conclusions: The combination of eribulin and capecitabine was well tolerated with no unexpected safety findings. Schedule 2 MTD (1.4 mg/m 2 Days 1 and 8) delivered a higher dose intensity of eribulin than Schedule 1 and was selected for evaluation in an ongoing Phase II breast cancer study. [Table: see text]
LONG TERM EFFICACY FOR CRYOBALLOON PULMONARY VEIN ISOLATION IN ATRIAL FIBRILLATION
Authors: Emily Guhl, Amr Barakat, Ankit Medhekar, Richard Pham, Raveen Bazaz, Norman Wang, Andrew Voigt, Krishna Kancharla, Aditya Bhonsale, N.A. Mark Estes, Samir F. Saba, Sandeep Jain
Journal: Journal of the American College of Cardiology (2020)